Search
Now showing items 1-10 of 13
Marine compounds in the treatment of Alzheimer’s disease
(Brac University, 2022-03)
Brain shrinkage and cell death occurs due to Alzheimer's disease, a degenerative neurologic illness. Memory loss, social and behavioral deterioration, and the inability to operate independently are all symptoms of Alzheimer's ...
Emerging therapies of Alzheimer’s disease: a comprehensive review
(Brac University, 2022-11)
Alzheimer’s disease is a complex, debilitating neurodegenerative disorder, with a rapidly increasing worldwide prevalence. Despite decades of intense research, therapeutics for Alzheimer's disease are still limited to ...
Glymphatic system: a pathway for managing endogenous metabolites in CNS
(Brac University, 2017-11)
Glymphatic pathway is one of the recent discoveries of neuro pharmacology which is a brainwide
paravascular system to exchange cerebrospinal fluid (CSF) and interstitial fluid. This
system is associated with the clearance ...
Application of microRNA (miRNA) in Alzheimer’s Disease (AD)
(Brac University, 2022-03)
Alzheimer's disease is a fatal illness that primarily affects older generations; its pathology pathways include beta-amyloid, tau protein, and activated microglia, destruction of synapse and no disease-modifying medication ...
Prospective detection methods for Tau protein: an important biomarker for Alzheimer’s disease
(Brac University, 2021-11)
Tau protein is one of the keystones in the diagnosis of Alzheimer’s disease. The modern detection techniques have come up to visualize, track and assess tau pathology and have further contributed with information about tau ...
Progress of finding latent therapeutic activity of vaccine for Alzheimer’s disease
(Brac University, 2019-05)
Alzheimer’s disease is one of leading diseases which provokes different internal
physiological conditions that ease deterioration of normal body mechanism among people
over 60 years of age. The proper pathophysiology of ...
Efficacy of Rivastigmine in Alzheimer’s disease- A structured seview
(Brac University, 2022-10-30)
Rivastigmine is an anti-cholinesterase agent, used to treat mild to moderate dementia of
Alzheimer’s disease (AD). Its efficacy and tolerability increase the treatment compliance. This
study focused on determining the ...
Epigenetic dysregulation in neurodegenerative diseases and potential treatment
(Brac University, 2022-04)
Epigenetics holds significant relevance in the contemporary neuroscience and has been associated with the pathogenesis of different neurodegenerative disorders. Epigenetic modifications including DNA methylation and histone ...
A pharmacovigilance study on Donepezil: signal detection of rhabdomyolysis and death
(Brac University, 2023-02)
Alzheimer’s disease is an age-related neurodegenerative disease that effects the cognitive ability of a person. The cholinesterase inhibitor “donepezil” is used to treat Alzheimer's disease. Donepezil has shown the greatest ...
A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease
(BRAC University, 2018-08)
Alzheimer’s disease (AD), a deadly neurodegenerative disease, which is considered as one of the top causes of death for people who are over 65 years of age. Up until now, no drug has been developed that can cure this disease ...